Proteínas asociadas a vesículas extracelulares tumorales como biomarcadores potenciales en el diagnóstico, progresión y supervivencia en diferentes tipos de cáncer
No Thumbnail Available
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
La investigación tuvo como objetivo evaluar proteínas asociadas a vesículas extracelulares tumorales como biomarcadores potenciales en el diagnóstico, progresión y supervivencia de diferentes tipos de cáncer. Los datos proteómicos primarios fueron obtenidos de bancos de datos de acceso abierto de TCGA para 20 tipos de cáncer y HPA/GTEx para la contraparte en individuos sanos. El valor diagnóstico fue obtenido a partir de 5895 muestras proveniente de pacientes con cáncer y 626 muestras provenientes de individuos sanos; el valor pronóstico se determinó con datos de 5494 pacientes supervivientes y 2202 fallecidos. Se estimó el Q-Score de 06 proteínas (CD9, PDCD6IP, HSPA8, ANXA2, ANXA5 y ANXA1) como biomarcadores diagnósticos, siendo la expresión de ANXA1 la más común al alza y a la baja (9 y 8 tipos de cáncer respectivamente). Las expresiones diferenciales pronósticas no favorables mayores fueron GAPDH en cáncer renal; PGK1 en cáncer mamario y ENO1 en cáncer hepático. Para las proteínas de pronóstico favorable las de mejor valor fueron PDCD6IP en cáncer renal; EEF2 en cáncer endometrial y TUBB4B en cáncer tiroideo. La supervivencia a 5 años de los pacientes que expresaron a la baja proteínas pronósticas no favorables fueron: 99% para CCT2 en cáncer prostático; 97% para TFRC en cáncer tiroideo; 87% para PGK1 en cáncer mamario; 83% para YWHAZ en cáncer endometrial 81% para FLOT1 en cáncer colorrectal. La supervivencia a 5 años de los pacientes que expresaron al alza proteínas pronósticas favorables fueron: 100% y 97% para ANXA1 y CD9 en cáncer tiroideo; 90% y 97% para TUBB4B en cáncer endometrial y cáncer tiroideo; y 89% para GNAI2 en cáncer mamario.
The research aimed to evaluate tumor extracellular vesicle-associated proteins as potential biomarkers in the diagnosis, progression and survival of different types of cancer. The primary proteomic data were obtained from open access TCGA databanks for 20 cancer types and HPA/GTEx for the counterpart in healthy individuals. The diagnostic value was obtained from 5895 samples from cancer patients and 626 samples from healthy individuals; the prognostic value was determined with data from 5494 surviving and 2202 deceased patients. The Q-Score of 06 proteins (CD9, PDCD6IP, HSPA8, ANXA2, ANXA5 and ANXA1) as diagnostic biomarkers was estimated, with ANXA1 expression being the most common up- and down-regulated (9 and 8 cancer types respectively). The highest unfavorable prognostic differential expressions were GAPDH in renal cancer; PGK1 in breast cancer and ENO1 in liver cancer. For the favorable prognostic proteins the best value were PDCD6IP in renal cancer; EEF2 in endometrial cancer and TUBB4B in thyroid cancer. The 5-year survival of patients who down-expressed unfavorable prognostic proteins were: 99% for CCT2 in prostate cancer; 97% for TFRC in thyroid cancer; 87% for PGK1 in breast cancer; 83% for YWHAZ in endometrial cancer; 81% for FLOT1 in colorectal cancer. The 5-year survival of patients who up-expressed favorable prognostic proteins were: 100% and 97% for ANXA1 and CD9 in thyroid cancer; 90% and 97% for TUBB4B in endometrial cancer and thyroid cancer; and 89% for GNAI2 in breast cancer.
The research aimed to evaluate tumor extracellular vesicle-associated proteins as potential biomarkers in the diagnosis, progression and survival of different types of cancer. The primary proteomic data were obtained from open access TCGA databanks for 20 cancer types and HPA/GTEx for the counterpart in healthy individuals. The diagnostic value was obtained from 5895 samples from cancer patients and 626 samples from healthy individuals; the prognostic value was determined with data from 5494 surviving and 2202 deceased patients. The Q-Score of 06 proteins (CD9, PDCD6IP, HSPA8, ANXA2, ANXA5 and ANXA1) as diagnostic biomarkers was estimated, with ANXA1 expression being the most common up- and down-regulated (9 and 8 cancer types respectively). The highest unfavorable prognostic differential expressions were GAPDH in renal cancer; PGK1 in breast cancer and ENO1 in liver cancer. For the favorable prognostic proteins the best value were PDCD6IP in renal cancer; EEF2 in endometrial cancer and TUBB4B in thyroid cancer. The 5-year survival of patients who down-expressed unfavorable prognostic proteins were: 99% for CCT2 in prostate cancer; 97% for TFRC in thyroid cancer; 87% for PGK1 in breast cancer; 83% for YWHAZ in endometrial cancer; 81% for FLOT1 in colorectal cancer. The 5-year survival of patients who up-expressed favorable prognostic proteins were: 100% and 97% for ANXA1 and CD9 in thyroid cancer; 90% and 97% for TUBB4B in endometrial cancer and thyroid cancer; and 89% for GNAI2 in breast cancer.
Description
Keywords
Cáncer, Expresión diferencial, Proteínas